Adam Sims joins the board at the contract manufacturing organisation (CMO) and brings with him a 20 year track record in the global pharmaceutical and chemical sector.
Mr Sims is the latest top-level appointment at SCM Pharma in the last year after it took on Graham Dotchin as its commercial director and Neal Wesley as the technical director.
Having spent seven years at Aesica in senior commercial and finance roles, Mr Sims will play a major advisory role in SCM Pharma’s ongoing expansion plans. He said: "I have always been impressed with SCM Pharma’s ambitious nature and have watched with interest its continued growth over the last few years.
"After visiting its sterile manufacturing facility, I was taken aback by its jaw-dropping technology. It is certainly the finest CMO site I have ever come across in the world and provides a solid foundation for a fantastic business.
"I am looking forward to supporting the executive team with my industry contacts, experience and knowledge to help ensure it continues to maintain its high profile, thrive as an independent business and achieve its commercial objectives."
The CMO recently picked up a major commercial supply project with Speciality European Pharma for its oncology product Plenaxis®. This followed the securing of a sterile filling project with Italian firm Molteni Therapeutics for a Phase II clinical trial.
Dianne Sharp, managing director at SCM Pharma, said: "We are delighted to have Adam on board as he brings a great deal of experience and market expertise that will hugely benefit our organisation.
"It’s certainly been a positive period for the company in terms of new projects and ongoing recruitment, but we’re not the type to rest on our laurels so are very much strengthening and looking at making our exciting future plans a reality."
SCM Pharma supports clients with finished product supply for clinical trials and commercial markets. It is able to fill liquids, gels and powders into a range of presentations including vials, ampoules, syringes, bottles and cartridges.
The award-winning manufacturer operates from its MHRA-licensed facility and now employs around 55 people. Alongside its capability to aseptically manufacture potent drugs such as cytotoxic and cytostatic compounds, SCM Pharma is also licensed for the sterile fill finish of C14 radiolabeled products to GMP standards.